GLP-1 for Sleep Apnea: Tirzepatide, Semaglutide, and OSA Research

Sleep apnea and weight are deeply connected

If you have been told to lose weight to improve your sleep apnea, you understand the frustration. The advice is not wrong, but it often comes across as simple when the reality is not. Weight and sleep apnea are connected through biology, not character. And newer evidence shows that at least one GLP-1-based medication can meaningfully improve sleep apnea in people with obesity.

Sleep apnea is a condition where your airway collapses or narrows repeatedly during sleep, blocking airflow and waking you up. The more excess tissue in your throat and neck, the more likely this is to happen. Excess weight is one of the main risk factors for obstructive sleep apnea (OSA) that can be changed, which is why weight loss is a standard part of OSA care for people with obesity.

This is why researchers began testing whether GLP-1 medications, which can lead to significant weight loss, could improve sleep apnea severity. For tirzepatide, a large trial says yes.

The connection between obesity and sleep apnea

Obstructive sleep apnea happens when soft tissue in your throat collapses during sleep, blocking your airway. Your body momentarily wakes you up so you can breathe again. This can happen dozens or even hundreds of times per night.

Obesity raises OSA risk because fat deposits around the neck and throat can narrow the airway and make it more likely to collapse. Sleep apnea is common in people with obesity, and many people with OSA have obesity.

Weight change and sleep apnea severity move together. In a long-term study of about 690 adults in Wisconsin, a 10% weight loss predicted about a 26% decrease in the apnea-hypopnea index (AHI), and a 10% weight gain predicted about a 32% increase^[3]. For some people, significant weight loss improves OSA from severe to mild or resolves it; for others, it helps but does not cure it.

The challenge has always been that weight loss is difficult for many people, especially those with obesity-related metabolic dysfunction. This is where GLP-1 medications enter the picture.

The SURMOUNT-OSA trial: What changed

On December 20, 2024, the FDA approved Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea in adults with obesity, in combination with a reduced-calorie diet and increased physical activity^[1][4]. This approval was based on the SURMOUNT-OSA trials, published in the New England Journal of Medicine in 2024^[2].

Here is what the trials showed.

Researchers ran two parallel 52-week trials with a combined 469 adults who had moderate to severe OSA and obesity. One trial enrolled people who were not using positive airway pressure (PAP) therapy such as CPAP. The other enrolled people already using PAP. Participants received either tirzepatide (the highest dose they tolerated, 10 mg or 15 mg weekly) or placebo.

The primary outcome was change in the apnea-hypopnea index (AHI), which measures sleep apnea severity. A lower AHI means less frequent breathing interruptions.

In the trial without PAP, AHI fell by an average of 25.3 events per hour with tirzepatide, compared with 5.3 events per hour with placebo^[2]. In the trial with PAP, AHI fell by 29.3 events per hour with tirzepatide, compared with 5.5 with placebo^[2]. In percentage terms, AHI fell by about 51% and 59% with tirzepatide, compared with about 3% and 2.5% with placebo^[1].

Average weight loss with tirzepatide was 17.7% and 19.6% of baseline body weight at 52 weeks, compared with 1.6% and 2.3% with placebo^[1]. The most common side effects with tirzepatide were gastrointestinal and mostly mild to moderate^[2]. Results vary. Trial results describe study participants and are not a prediction for any individual.

These were large, randomized, placebo-controlled trials, and they are the basis for tirzepatide’s OSA indication. The trials were funded by Eli Lilly and studied the brand-name product only.

How weight loss improves sleep apnea

The mechanism is straightforward. Reducing body weight, particularly upper body fat, decreases the amount of soft tissue compressing your airway during sleep. This makes airway collapse less likely.

When you lose weight, you are not just losing scale pounds. You may be reducing the fat deposits in your neck and throat that narrow your airway, which can lower AHI and improve oxygen levels during sleep.

This is why the benefit is most relevant for people whose sleep apnea is driven mainly by excess weight. It is also why weight loss does not guarantee complete resolution of OSA. Other anatomical factors (jaw position, tonsil size, nasal passages) also contribute. For some people, significant weight loss resolves OSA. For others, it improves OSA but does not cure it.

Your sleep specialist can monitor your AHI and oxygen levels as your weight changes to see how much improvement you get.

Tirzepatide vs. semaglutide for sleep apnea

Tirzepatide has direct clinical trial evidence for sleep apnea improvement through the SURMOUNT-OSA trials, and the brand-name product Zepbound carries an FDA-approved OSA indication^[1].

Semaglutide is not FDA-approved to treat OSA; the Wegovy label covers weight management and other conditions, not sleep apnea^[5]. Semaglutide also leads to weight loss and could plausibly help OSA through the same weight-related mechanism, but it does not have a comparable large OSA trial behind an FDA indication.

If sleep apnea is a key concern for you, tirzepatide is the medication with OSA-specific trial evidence. If you have other health considerations alongside OSA, the licensed provider you choose may recommend semaglutide or another option. The decision is individualized based on your complete health history.

Important note: The SURMOUNT-OSA trials studied only the brand-name tirzepatide product. Compounded tirzepatide is not FDA-approved, has no FDA-approved indication for OSA, and has not been evaluated in OSA trials.

Sleep apnea as a qualifying condition for GLP-1 treatment

Obstructive sleep apnea is recognized as a weight-related condition. The FDA labels for GLP-1 weight management medications such as Zepbound and Wegovy cover adults with obesity (BMI of 30 or higher) and adults with overweight (BMI of 27 or higher) who have at least one weight-related condition^[1][5]. Separately, Zepbound’s OSA indication covers adults with moderate to severe OSA and obesity^[1].

Meeting a label’s BMI range does not mean a prescription is automatic. A licensed provider reviews your complete health history, including your OSA diagnosis, current CPAP use, oxygen levels during sleep, other conditions, medications, and your weight, and decides whether GLP-1 treatment is appropriate and safe for you.

A GLP-1 medication is not the right fit for everyone with sleep apnea. Talk with a licensed provider about your situation.

Managing CPAP and GLP-1 treatment together

If you are currently using CPAP therapy, the SURMOUNT-OSA program included a trial of people already using PAP, who continued it during the study^[2]. That shows the two have been used together under study conditions.

As your weight and AHI change, your sleep specialist may recommend adjusting your CPAP settings. The FDA label notes that the OSA trials did not evaluate the timing or appropriateness of stopping PAP in people who were already using it^[1]. Any change to CPAP should be based on a follow-up sleep study and your oxygen levels.

These are decisions your sleep specialist makes based on your specific sleep study results. Do not adjust or discontinue CPAP on your own. Make sure your sleep specialist and the provider who prescribes your GLP-1 medication both know about each other’s treatment.

Results vary. Trial results describe study participants and are not a prediction for any individual.

How the process should work

At most telehealth programs, you complete a health history and a licensed provider decides whether a prescription is appropriate. If you have sleep apnea, a careful review should cover:

• Your OSA diagnosis and severity. Your most recent sleep study, AHI, and oxygen levels, if you have them.
• Your current treatment. Whether you use CPAP or another device, and how consistently.
• Your full health history. Other conditions, all medications and supplements, and any history of pancreatitis, gallbladder disease, or thyroid cancer in you or your family.
• Coordination with your sleep specialist. Whether the prescriber will share information with, or ask you to follow up with, the clinician who manages your OSA.
• A real decision. A review that can end in “no”, not an automatic approval.

Some states require a live video or phone visit before a prescription can be written, and programs handle this differently. Ask the program what applies in your state.

What to check before using tirzepatide or semaglutide

If you are comparing programs, these questions help you see what you are actually getting:

• Is the medication brand-name or compounded? Only brand-name Zepbound is FDA-approved for OSA. Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality. They are not the same as brand-name products and may differ in formulation, purity, and potency.
• Who prepares compounded medication? If a program offers compounded medication, ask which pharmacy prepares it and in which state it is licensed.
• What is the total cost? Prices vary by program and dose. Compare medication, dose increases, provider visits, labs, shipping, membership fees, and cancellation terms.
• Are labs included or billed separately? Some programs include baseline labs; others bill separately or ask you to use your own provider.
• How is follow-up handled? Ask how often the prescriber checks in during dose increases and what happens if side effects make it hard to continue.

Transformation Health does not accept payment from providers. How we make money.

How to get started

Start with the clinician who manages your sleep apnea. Ask whether weight loss is likely to help your OSA, whether a GLP-1 medication makes sense alongside your current treatment, and how you would monitor changes with a follow-up sleep study.

If you want to understand who the FDA labels cover before talking with a provider, see the GLP-1 Eligibility Guide.

For a detailed comparison of semaglutide and tirzepatide, including how they differ for specific situations, see Semaglutide vs Tirzepatide.

Transformation Health is relaunching as an independent GLP-1 guide with a free custom report that compares programs. Leave your email to be told when the report is available.

Citations

[1] Eli Lilly and Company. Zepbound (tirzepatide) injection, prescribing information, revised 08/2026, sections 1 (Indications and Usage) and 14.2 (Obstructive Sleep Apnea Studies in Adults with Obesity). https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf

[2] Malhotra A, et al. “Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.” New England Journal of Medicine. 2024;391(13):1193-1205. https://pubmed.ncbi.nlm.nih.gov/38912654/

[3] Peppard PE, et al. “Longitudinal study of moderate weight change and sleep-disordered breathing.” JAMA. 2000;284(23):3015-3021. https://pubmed.ncbi.nlm.nih.gov/11122588/

[4] U.S. Food and Drug Administration. Drugs@FDA: Zepbound, NDA 217806, efficacy supplement 13 approved 12/20/2024. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806

[5] U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information, section 1 (Indications and Usage). Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf